Montag & Associates’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Montag & Associates’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-100	Closed	-$2.41K	–	952
2023 Q1	$2.41K	Hold	100	–	–	﹤0.01%	858
2022 Q4	$1.06K	Buy	+100	New	+$807	﹤0.01%	902

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Montag & Associates's PRVB Position: Q2 2023 in Review

Montag & Associates sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 100 shares — an estimated $2.41K sold.

Montag & Associates first reported a position in PRVB in Q4 2022 and held it in 2 quarters. The position peaked at $2.41K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Montag & Associates reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Montag & Associates sold 100 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $2.41K.
Montag & Associates first reported a position in Provention Bio, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Montag & Associates's Provention Bio, Inc. Common Stock position peaked at $2.41K in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Montag & Associates's 13F filing for Q2 2023, filed 9 Aug 2023.